Jivolar

Metformin Hydrochloride and Sitagliptin, the active ingredient in Jivolar, is a biguanide and DPP‑4 inhibitor presented as a tablet for oral use. It treats type 2 diabetes mellitus in adults.

GNH USA supplies Jivolar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Jivolar is an oral antidiabetic medication used to improve glycaemic control in type 2 diabetes mellitus.

- Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels. - Adjunct to diet and exercise: helps patients achieve target HbA1c when lifestyle changes alone are insufficient. - Combination therapy: used when metformin or sitagliptin monotherapy does not provide adequate control.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea. - Headache: mild to moderate intensity. - Mild hypoglycaemia: especially when combined with other glucose‑lowering agents.

Serious or Rare Side Effects: - Lactic acidosis: a rare but potentially fatal metabolic complication. - Severe hypoglycaemia: can occur with concomitant insulin or sulfonylureas. - Pancreatitis: acute inflammation of the pancreas. - Allergic reactions: rash, angioedema, or anaphylaxis. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Jivolar should be used with careful monitoring of renal and hepatic function and awareness of hypoglycaemia risk.

- Renal function monitoring: assess eGFR before initiation and periodically thereafter. - Hepatic function monitoring: evaluate liver enzymes at baseline and during therapy. - Risk of lactic acidosis: avoid in patients with severe renal impairment or acute heart failure. - Use with caution in elderly patients: increased susceptibility to adverse events. - Contraindicated in severe heart failure: may exacerbate metabolic acidosis. - Store at room temperature: keep in the original pack, protect from moisture.

Jivolar may interact with several drug classes, requiring dose adjustments or monitoring.

Major Interactions (Avoid): - Other biguanides (e.g., phenformin): increase risk of lactic acidosis. - Insulin secretagogues (sulfonylureas, meglitinides): potentiate hypoglycaemia. - Iodinated contrast agents: may precipitate acute renal failure. - Alcohol excess: heightens lactic acidosis risk. - Strong CYP3A4 inhibitors (e.g., ketoconazole): raise sitagliptin levels.

Moderate Interactions (Monitor Closely): - Diuretics (thiazides, loop diuretics): affect renal clearance of metformin. - ACE inhibitors/ARBs: combined impact on renal function. - NSAIDs: may reduce renal perfusion, increasing metformin accumulation. - Beta‑blockers: can mask hypoglycaemia symptoms. - Warfarin: monitor INR as sitagliptin may alter anticoagulant effect.